Mounjaro vs Saxenda

Mounjaro (tirzepatide) and Saxenda (liraglutide 3 mg) represent two different generations of incretin-based medications used for weight management. Mounjaro is a dual GIP/GLP-1 receptor agonist administered as a once-weekly injection, FDA-approved for type 2 diabetes (its weight-loss formulation is marketed as Zepbound). Saxenda is a once-daily GLP-1 receptor agonist that was FDA-approved for chronic weight management in 2014 and was considered a breakthrough when it launched.

The difference in weight loss efficacy between these two medications is substantial. In the SURMOUNT-1 trial, tirzepatide at the highest dose (15 mg) produced mean weight loss of approximately 22.5% over 72 weeks in adults with obesity. In the SCALE trial, liraglutide 3 mg produced mean weight loss of approximately 8% over 56 weeks. While these results come from separate trials with different designs and populations -- making direct comparison imprecise -- the magnitude of the difference suggests a meaningful generational advance. Tirzepatide's dual receptor mechanism is believed to contribute to its greater efficacy.

Saxenda requires daily injections and a multi-week dose titration schedule, while Mounjaro is injected weekly. Both medications cause gastrointestinal side effects such as nausea and vomiting, which are common across the GLP-1 drug class. Saxenda has a longer post-market safety track record given its earlier approval. Cost and insurance coverage differ significantly between the two, and availability may vary. Patients considering either medication for weight management should consult their healthcare provider to evaluate which option aligns with their medical history, treatment goals, and access considerations.